Lee Pharmaceuticals, Inc. (AIMN) Stock Analysis
Verdict: AVOID
A defunct OTC shell in an apparent death spiral, the ticker exhibits catastrophic capital destruction with no evidence of surviving operations.
Investment score: 2/100
Analysis as of
Is Lee Pharmaceuticals, Inc. stock worth reviewing? The TradeMates thesis
The TradeMates model views AIMN as a 'zombie' ticker representing a defunct business. With no revenue, no management, and a price that has fallen from $12.00 to $0.004 in one year, the risk of permanent capital loss is near 100%.
7-factor investment score
- Valuation: 0/100 (weight 20%)
- Financial Health: 0/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 0/100 (weight 15%)
- Insider Sentiment: 0/100 (weight 10%)
- Analyst Consensus: 0/100 (weight 10%)
- Risk-Adjusted Return: 0/100 (weight 15%)
Lee Pharmaceuticals, Inc. opportunities and risks
What speaks for AIMN
- Reverse Merger Candidate
What speaks against AIMN
- Permanent Delisting
Frequently asked questions about Lee Pharmaceuticals, Inc. (AIMN)
Is AIMN stock a good investment?
The TradeMates model rates Lee Pharmaceuticals, Inc. as AVOID with an investment score of 2/100. The TradeMates model views AIMN as a 'zombie' ticker representing a defunct business. With no revenue, no management, and a price that has fallen from $12.00 to $0.004 in one year, the risk of permanent capital loss is near 100%. This is algorithmic model output, not personal investment advice.
Is AIMN stock a buy?
The TradeMates model verdict for AIMN is AVOID with an investment score of 2/100. Treat this as a model signal to review, not a personal buy recommendation.